LncRNA expression profile, functional analysis and potential biomarkers in children with pancreaticobiliary maljunction

Lian Zhao
Soochow University Affiliated Children's Hospital
San-li Shi
Xi'an Jiaotong University Second Affiliated Hospital
Wan-liang Guo (gwlsuzhou@163.com)
Xi'an Jiaotong University Second Affiliated Hospital

Research article

Keywords: pancreaticobiliary maljunction, long non-coding RNAs, gene ontology, biomarker

DOI: https://doi.org/10.21203/rs.3.rs-558683/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The present study was aimed to investigate the expression profile of long non-coding RNAs (lncRNAs) and its potential as biomarker for pancreaticobiliary maljunction (PBM).

Methods

The differential expression of lncRNA and messenger RNA (mRNA) from 15 pediatric patients with PBM and 15 control subjects were analyzed with microArray and validated with quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Gene Ontology enrichment and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis were used to investigate the biological functions of these genes. The area under curve (AUC) of receiver operating characteristic (ROC) curve was used to predict the biomarker of lncRNA in PBM.

Results

There were 2915 mRNAs and 173 lncRNAs upregulated, 2121 mRNAs and 316 lncRNAs downregulated in PBM cases, respectively. The enriched GO associated with differentially expressed mRNA were extracellular matrix, extracellular region and kinetochore. The most enriched pathway of Protein digestion and absorption was associated with cancer and PI3K-Akt signaling. Cis- and Trans-target gene analysis indicated that mRNAs were predicted to be regulated by one lncRNA and one mRNA corresponded to several lncRNAs. The results showed that the expression trends of NR_110876, NR_132344, XR_946886 and XR_002956345 were consistent with the microarray results, and the difference was statistically significant NR_132344, XR_946886 and XR_002956345 (P < 0.05). The AUC of ROC curve was significant only for XR_946886 (0.837, P < 0.001).

Conclusion

The present study indicated that lncRNAs were involved the pathogenesis of common bile duct in PBM and XR_946886 would be biomarkers for PMB.

Background

Pancreaticobiliary maljunction (PBM) is a rare congenital anomaly observed in clinical practice, in which the junction of pancreatic and the biliary ducts is located outside the duodenal wall [1, 2, 3]. Due to two-way reflux of bile and pancreatic juice in PBM, bile retention with cholangitis, pancreatitis and malignancies are commonly associated complications in PBM [4, 5, 6].

Cyst excision and Roux-en-Y hepaticojejunostomy is the first choice for PBM treatment in clinic [7, 8, 9]. However, the postoperative problems in bile duct, such as cholangitis, hepatolithiasis and carcinogenesis at the residual bile ducts [8,10,11,12,13] are worthy of attention. Thus, it is urgent to investigate the biomarkers that link PBM to the related complications of bile duct, in order to early detect the complications in PBM and develop effective diagnostic and therapeutic methods.

Long noncoding RNAs (lncRNAs), a group of non-coding RNAs longer than 200 nt, play an important role in regulating the occurrence and progression of many diseases, such as infectious and malignant tumors [14, 15, 16], through modulating biological processes, such as cellular proliferation, motility, immune and inflammation response to diseases [17, 18, 19]. In addition, some lncRNAs has been identified as biomarkers for diagnosis and prognosis of diseases [20, 21]. However, the genome-wide expression and functional roles of lncRNAs in PBM is unclear.

To the best of our knowledge, there has been no publication focused on lncRNAs in common bile duct of PBM and PBM-linked biologic markers. Here, we investigated the expression profiles, functional analysis and potential biomarkers of lncRNAs in the common bile duct of patients with PBM. Our findings would provide basis for developing novel diagnostic and therapeutic targets for PBM.

Material And Methods

1. Study subjects

The present study was approved by the institutional review board of the Children's Hospital of Soochow University. Written informed consent was signed by the guardian of the subjects before surgery. A total of 15 subjects with PBM and 15 normal subjects as control were enrolled in
the present study. The expression of lncRNA and mRNA was analyzed with microarrays and verified with qRT-PCR. The clinical and pathological characteristics of the 15 patients were summarized in Table 1.

2. RNA Microarray analysis

Microarray experiments to investigate the differentially expressed genes between PBM and control group were performed by Western SCI Biotech Company, Chongqing, China (http://www.westernsci.cn). The Agilent Human lncRNA Microarray 2018 Version (4*180k, Design ID: 085630) was used in this experiment.

The tissue of common bile duct of PBM cases were collected and stored at −80 °C before RNA extraction. Total RNA was isolated using TRIZOL (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol and quantified by the NanoDrop ND-2000 (Thermo Scientific). The RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies). The sample labeling, microarray hybridization and washing were performed based on the manufacturer's standard protocols. Briefly, total RNA was transcribed to double strand cDNA, then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned by the Agilent Scanner G2505C (Agilent Technologies).

For data analysis, the Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze the array images to get raw data. Genespring (version 13.1, Agilent Technologies) were employed to finish the basic analysis with the raw data. To begin with, the raw data was normalized with the quantile algorithm. The probes that at least 1 out of 2 conditions have flags in “P” were chosen for further data analysis. Differentially expressed genes or IncRNAs were then identified through fold change. The threshold set for up- and down-regulated genes was a fold change >= 2.0. Afterwards, gene ontology (GO) analysis and KEGG analysis were applied to determine the roles of these differentially expressed mRNAs and IncRNAs. Finally, Hierarchical Clustering was performed to display the expression pattern of distinguishable genes among different samples.

3. LncRNA function prediction

For function prediction of lncRNAs, we adopted the method from previous study [22]. In brief, the co-expressed mRNAs for each differentiated IncRNAs were calculated and subjected to functional enrichment analysis. The enriched functional terms were used as the predicted functional term of a given IncRNA. The co-expressed mRNAs of IncRNAs were identified by calculating the Pearson correlation with correlation P-value <0.05. The Hypergeometric cumulative distribution function was used to calculate the enrichment of functional terms in annotation of co-expressed mRNAs. The relationship between IncRNA and function prediction terms, the top 200 and top 500 prediction relationships with the highest prediction reliability were selected. The frequency of each functional prediction term was counted, and the GO or pathway term with more functional annotation was counted to reflect the overall situation of the functional distribution of different IncRNA. The top 20 significant IncRNAs were selected to draw a bar chart.

4. Fine mapping of genome coexpression of IncRNAs and adjacent coding genes

The Cis-regulatory regions were identified by the following procedures. For each IncRNAs, the mRNAs were identified as "Cis-regulated mRNAs" when: (1) the mRNAs loci were within 300k windows up- and down-stream of the given IncRNA, (2) the Pearson correlation of IncRNA-mRNA expression was significant (P-value of correlation <=0.05).

For each differentially expressed IncRNAs, the co-expressed genes and the enrichment significance of differentially expressed gene in each transcription factor (TF) entry was calculated by hypergeometric distribution test. The calculated results will return a p value of enrichment significance, and a small P value indicates that the gene is enriched in the TF entry.

The intersection between the coding gene set co-expressed by IncRNAs and the target gene set of TF/chromatin regulatory complex was calculated, and the enrichment degree of the intersection was calculated by using hypergeometric distribution test. This calculation obtained the TF significantly related to IncRNAs and identified the TF/chromatin regulatory factors that may play a regulatory role with IncRNAs. And the network diagram visualized using the analysis results of hypergeometric distribution.

According to hypergeometric distribution calculation, multiple IncRNA-TF pairs were obtained from each IncRNA. Each IncRNA-TF pair was the result of multiple gene enrichment.

5. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) Assay

In order to verify the microarray results, we randomly selected a total of 6 differently expressed IncRNAs that associate with carcinogenesis or chronic inflammation in common bile duct in PBM cases and measured the IncRNA expression levels of these genes by qRT-PCR. qRT-PCR was...
performed using SYBR Green PCR Kit (Applied BI) according to the manufacturer’s instructions. Gene expression was normalized to β-actin lncRNA. The relative expression of gene transcript was calculated using the $2^{-\Delta\Delta Ct}$ method.

6. **Statistical Analysis**

SPSS 20.0 software was used for statistical analysis. The results of measurement data were expressed as mean ± SD. The comparison between the groups was performed using the rank sum test. A fold change of 2.0 ($P < 0.05$) was used as a cutoff for differential expression of lncRNAs and mRNAs screened by microarray. Receiver operator characteristic (ROC) curve analysis was conducted and area under the ROC curve (AUC) was calculated to evaluate the diagnostic accuracy of selected genes in PBM patients. $P < 0.05$ was considered statistically significant.

**Results**

1. **General information**

A total of 15 pediatric subjects with PBM and 15 control subjects were included in the study. Demographic and clinical data were summarized in Table 1. There was no significant difference between 2 groups in body weight, age, gender or other general information.

2. **Differential gene expression between subjects with PBM and control subjects**

From the microarray data, there were 2915 mRNAs upregulated, 2121 mRNAs downregulated, 173 lncRNAs upregulated and 316 lncRNAs downregulated in subjects with PBM (cut-off = 2.0). Principal Component Analysis (PCA) results of differentiated lncRNA and heatmap were presented in figure 1. The top 20 upregulated and downregulated lncRNAs were presented in Tables 2. The most upregulated lncRNA was LOC105378608 with fold change of 14.39.

3. **Functional analysis of differentially expressed genes**

To avoid omission of any PBM–related genes, we performed functional analyses for all the differentially expressed mRNAs. It was found that the most enriched GOS associated with the differentially expressed transcripts were extracellular matrix ($p=2.9E-12$, up-regulated), extracellular region ($p=0.000427$, up-regulated), and kinetochore ($p=2.29E-8$, up-regulated) (Figure 2). The most enriched pathway was Protein digestion and absorption which could be related to 250 differentially expressed genes. Some pathways were associated with cancer, such as pathways in cancer (associated with 11 genes), PI3K-Akt signaling pathway (associated with 15 genes, Figure 3).

4. **Co-expression analysis and target prediction**

The functions of lncRNAs were performed by inter-acting with their targets. In the present study, the potential cis- and trans-acting were predicted. The mRNAs 100 kb upstream and downstream of the lncRNAs were searched for cis analysis, and we found that 5 lncRNAs were related with cis target genes (Figure 4). The trans analysis of lncRNAs was performed by constructing co-expression networks (Fig. 5) of dysregulated mRNAs and lncRNAs based on the expression correlation coefficient (Pearson correlation P-value <0.05). The data showed that most lncRNAs acted in a trans-acting manner. The top 200 prediction relationships with the highest prediction reliability were selected to count the frequency of each TF, and the TF with more functional annotation was counted to reflect the overall functional distribution of different lncRNAs (Figure 6). With the detected 964 lncRNAs that corresponded to 9358 mRNAs, more than one mRNAs were predicted to be regulated by one lncRNA and one mRNA corresponded to several lncRNAs.

5. **qRT-PCR Validation**

The up-regulated genes (NR_110876, NR_132344, XR_946886, XR_002956345, NR_135295 and XR_002957935) that were associated with carcinogenesis or chronic inflammation in common bile duct were verified by qRT-PCR. The results showed that the expression trends of NR_110876, NR_132344, XR_946886 and XR_002956345 were consistent with the microarray results, and the difference was statistically significant NR_132344, XR_946886 and XR_002956345 ($P < 0.05$). However, the expression trends of NR_135295 and XR_002957935 were not consistent with the microarray results (Figure 6). To further assess the accuracy of NR_110876, NR_132344, XR_946886, XR_002956345 as biomarker in PBM, analysis of the ROC curve was performed with the AUC. The results indicated that only the AUC of XR_946886 was significantly different (0.837, $p<0.001$) (Figure 8).

**Discussion**
In PBM cases, the reflux of pancreatic juice into the bile duct could damage the bile duct wall and lead to bile duct dilatation, cholestasis, stone formation, epithelial hyperplasia and malignant transformation in the biliary tract [4,5,6,7]. The biological effects of reflux of pancreatic juice and its relationship with chronic inflammation and carcinogenesis have attracted great attention in recent years. Previous studies regarding the transcriptomes of congenital dilation of common bile duct (CDC) have discovered numerous novel transcriptomic alterations. Kaneko et al. identified several downregulated genes in the gallbladder of children with PBM which may contribute to the pathophysiology and found some upregulated noncoding RNAs that may be important for biliary carcinogenesis [23]. In our previous study [24], we found 876 differentially expressed genes in children with PBM, of which 530 genes were up-regulated and 346 genes were down-regulated. Wong et al. identified 21 damaging de novo variants (DNV) in 31 cases with CDD, 6 DNV-carrying genes associated with human developmental disorders and 4 DNV-carrying genes linked with cholangio- and hepatocellular carcinomas [25]. However, there is rare report about lncRNA in PBM patients.

In the present study, we identified 489 IncRNA and 5036 mRNA transcripts that were found differentially expressed in the bile duct tissues of patients with PBM. These differentially expressed IncRNAs may affect many pathways, including those involved in Protein digestion and absorption, ECM-receptor interaction, Focal adhesion, PI3K-Akt signaling, carcinogenesis and inflammation, which were consistent with previous studies [21-23]. These findings, together with our qPCR data, suggest that IncRNAs may contribute to PBM associated complication, such as carcinogenesis and chronic inflammation in common bile duct. Among these differentially expressed IncRNAs, the upregulation of NR_110876, NR_132344, XR_946886 and XR_002956345 was confirmed by qPCR; however, only XR_946886 showed significant difference in the AUC of ROC. The findings suggested that XR_946886 might be involved in the development of complication of PBM and could become new biomarkers for carcinogenesis or chronic inflammation in common bile duct in PBM.

The potential functions of IncRNAs were commonly predicted by their target genes. In the present study, the relationships between IncRNAs and their target genes collocated (within 100 kb) were analyzed. We found that 5 cis target genes were related with differentially expressed IncRNA and that most IncRNAs acted in a trans manner. For example, we found that E2F4 was closely associated with IncRNA and target genes, which is consistent with previous reports that E2F4 is associated with the development and progression of cancers [26,27].

There were some limitations in the present study. The sample size was relatively small and only six related IncRNAs identified in microarray experiments were validated via qRT-PCR. Future studies should be conducted with larger sample sizes and in-depth verification of more candidate genes. In addition, the potential mechanisms of XR_946886 and its clinical values in PBM still require further studies.

In summary, the present study provided an overall analysis of IncRNAs in common bile duct in PBM. By further exploring potential functions and pathways in which the IncRNAs were involved, we anticipate that IncRNAs such as XR_946886 will be biomarkers or even potential therapeutic targets for PMB treatment.

**Abbreviations**

long non-coding RNAs=IncRNAs; pancreaticobiliary maljunction=PBM; messenger RNA=mRNA; qRT-PCR= quantitative reverse-transcription polymerase chain reaction; ROC= receiver operator characteristic; GO= Gene Ontology; KEGG= Kyoto Encyclopedia of Genes and Genomes;

**Declarations**

**Ethics approval and consent to participate**

Informed written consent was obtained from all participants’ parents. The study protocol was approved by the Ethics Committee of the Children's Hospital of Soochow University, Suzhou, China (No. 20170506016).

**Consent for publication**

Written informed consent for publication of the case was obtained for each participant's parents.

**Availability of data and materials**

All data generated or analyzed during this study are included in this article.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**
This work was supported by National Natural Science Foundation (No.81971685). The funding bodies only provided the financial means to buy reagents for experiments, and the funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions

Study conception and design: WL G. Acquisition of data: LZ. Analysis and interpretation of data: SL S. Drafting of manuscript: LZ. Critical revision of manuscript: WL G. All authors have read and approved the manuscript.

Acknowledgements

Not applicable.

Authors’ information

Department of Radiology, Children's Hospital of Soochow University, Suzhou, China, 215025

References

1. Le Roy B, Gagnière J, Filaire L, Fontarensky M, Hordonneau C, Buc E (2016) Pancreaticobiliary maljunction and choledochal cysts: from embryogenesis to therapeutics aspects. Surgical and radiologic anatomy : SRA 38 (9):1053-1060. doi:10.1007/s00276-016-1669-y.
2. Kamisawa T, Kuruma S, Chiba K (2016) [Congenital biliary dilatation and pancreaticobiliary maljunction]. Nihon Shokakibyo Gakkai Zasshi 113 (12):1991-1997. doi:10.11405/nisshoshi.113.1991.
3. Urushihara N, Hamada Y, Kamisawa T, Fuji H, Koshinaga T, Morotomi Y, Saito T, Itoi T, Kaneko K, Fukuzawa H, Ando H (2017) Classification of pancreaticobiliary maljunction and clinical features in children. J Hepatobiliary Pancreat Sci 24 (8):449-455. doi:10.1002/jhbp.485.
4. Kamisawa T, Kuruma S, Tabata T, Chiba K, Iwasaki S, Koizumi S, Kurata M, Honda G, Itoi T (2015) Pancreaticobiliary maljunction and biliary cancer. J Gastroenterol 50 (3):273-279. doi:10.1007/s00535-014-1015-2.
5. Kamisawa T, Kaneko K, Itoi T, Ando H (2017) Pancreaticobiliary maljunction and congenital biliary dilatation. Lancet Gastroenterol Hepatol 2 (8):610-618. doi:10.1016/s2468-1253(17)30002-x.
6. Eda K, Mizuochi T, Takaki Y, Higashidate N, Hashizume N, Fukahori S, Asagiri K, Yamashita Y, Yagi M (2018) Adenomyomatosis of the Gallbladder With Pancreaticobiliary Maljunction in a Child. J Pediatr Gastroenterol Nutr 67 (4):e82. doi:10.1097/mpg.0000000000001367.
7. Ono S, Fumino S, Iwai N (2011) Diagnosis and treatment of pancreaticobiliary maljunction in children. Surg Today 41 (5):601-605. doi:10.1007/s00595-010-4492-9.
8. Kamisawa T, Ando H, Suyama M, Shimada M, Morine Y, Shimada H (2012) Japanese clinical practice guidelines for pancreaticobiliary maljunction. J Gastroenterol 47 (7):731-759. doi:10.1007/s00535-012-0611-2.
9. Guo WL, Zhan Y, Fang F, Huang SG, Deng YB, Zhao JG, Wang J (2018) Factors affecting the operating time for complete cyst excision and Roux-en-Y hepaticojejunostomy in paediatric cases of congenital choledochal malformation: a retrospective case study in Southeast China. BMJ Open 8 (5):e022162. doi:10.1136/bmjopen-2018-022162.
10. Tsuchida A, Kasuya K, Endo M, Saito H, Inoue K, Nagae I, Aoki T, Koyanagi Y (2003) High risk of bile duct carcinogenesis after primary resection of a congenital biliary dilatation. Oncol Rep 10 (5):1183-1187.
11. Kobayashi S, Asano T, Yamasaki M, Kenmochi T, Nakagohri T, Ochiya T (1999) Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. Surgery 126 (5):939-944. doi:10.1016/s0039-6060(99)70036-x.
12. Sheng Q, Lv Z, Xu W, Xiao X, Liu J, Wu Y (2017) Reoperation After Cyst Excision with Hepaticojejunostomy for Choledochal Cysts: Our Experience in 18 Cases. Med Sci Monit 23:1371-1377. doi:10.12659/msm.900313.
13. Sugiuira T, Endo T, Ito K, Goto K, Sato Y, Kondo S, Suzuki T, Hashimoto T (2013) Recurrent Cholangitis with Congenital Hepatic Fibrosis and Pancreaticobiliary Maljunction after Roux-en-Y Reconstruction. European J Pediatr Surg Rep 1 (1):43-45. doi:10.1055/s-0033-1341420.
14. Song W, Miao DL, Chen L (2018) Comprehensive analysis of long noncoding RNA-associated competing endogenous RNA network in cholangiocarcinoma. Biochem Biophys Res Commun 506 (4):1004-1012. doi:10.1016/j.bbrc.2018.10.186.
15. Jiang Y, Huang Y, Cai S, Song Y, Boyer JL, Zhang K, Gao L, Zhao J, Huang W, Liang G, Liangpunsakul S, Wang L (2018) H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4a(+) Periportal Hepatocytes but Not Cytokeratin 19(+) Cholangiocytes in Cholestatic Livers. Hepatol Commun 2 (11):1356-1368. doi:10.1002/hep4.1252.
16. Ren GJ, Fan XC, Liu TL, Wang SS, Zhao GH (2018) Genome-wide analysis of differentially expressed profiles of mRNAs, lncRNAs and circRNAs during Cryptosporidium baileyi infection. BMC Genomics 19 (1):356. doi:10.1186/s12864-018-4754-2.
17. Long X, Song K, Hu H, Tian Q, Wang W, Dong Q, Yin X, Di W (2019) Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res 38 (1):345. doi:10.1186/s13046-019-1329-2.

18. Tang Y, Zhou T, Yu X, Xue Z, Shen N (2017) The role of long non-coding RNAs in rheumatic diseases. Nat Rev Rheumatol 13 (11):657-669. doi:10.1038/nrrheum.2017.162.

19. Sallam T, Sandhu J, Tontonoz P (2018) Long Noncoding RNA Discovery in Cardiovascular Disease: Decoding Form to Function. Circ Res 122 (1):155-166. doi:10.1161/circresaha.117.311802.

20. Zhou M, Zhao H, Xu W, Bao S, Cheng L, Sun J (2017) Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer 16 (1):16. doi:10.1186/s12943-017-0580-4.

21. Song P, Jiang B, Liu Z, Ding J, Liu S, Guan W (2017) Three-lncRNA expression signature associated with the prognosis of gastric cancer patients. Cancer Med 6 (6):1154-1164. doi:10.1002/cam4.1047.

22. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassidy JP, Cabili MN, Jaenisch R, Mikkelson TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458 (7235):223-227. doi:10.1038/nature07672.

23. Kaneko K, Ito Y, Ono Y, Tainaka T, Tsuchiya H, Shimoyama Y, Ando H (2011) Gene expression profiling reveals upregulated UCA1 and BMF in gallbladder epithelia of children with pancreaticobiliary maljunction. J Pediatr Gastroenterol Nutr 52 (6):744-750. doi:10.1097/MPG.0b013e318214bd30.

24. Guo WL, Geng J, Zhao JG, Fang F, Huang SG, Wang J (2019) Gene expression profiling reveals upregulated FUT1 and MYBPC1 in children with pancreaticobiliary maljunction. Braz J Med Biol Res 52 (8):e8522. doi:10.1590/1414-431x20198522.

25. Wong JK, Campbell D, Ngo ND, Yeung F, Cheng G, Tang CS, Chung PH, Tran NS, So MT, Cherry SS, Sham PC, Tam PK, Garcia-Barcelo MM (2016) Genetic study of congenital bile-duct dilatation identifies de novo and inherited variants in functionally related genes. BMC Med Genomics 9 (1):75. doi:10.1186/s12920-016-0236-z.

26. Bhawe K, Roy D (2018) Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression. Cell Oncol (Dordr) 41 (5):465-484. doi:10.1007/s13402-018-0395-3.

27. Long X, Song K, Hu H, Tian Q, Wang W, Dong Q, Yin X, Di W (2019) Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res 38 (1):345. doi:10.1186/s13046-019-1329-2.

Tables

Table 1. The clinical and pathological characteristics of PBM

| Variables          | Todani types I (n=7) | Todani types IV (n=8) |
|--------------------|----------------------|-----------------------|
| Abdominal pain     | 6                    | 4                     |
| Jaundice           | 1                    | 4                     |
| Mass               | 0                    | 0                     |
| Fever              | 1                    | 1                     |
| Vomiting           | 5                    | 3                     |
| Gender (male)      | 0                    | 3                     |
| Age (months)       | 9-71                 | 4.5-50                |
| Pathological findings |                   |                       |
| Cyst wall hyperplasia | 7                   | 8                     |
| Gallbladder wall   | 7                    | 8                     |

Table 2: The top 20 differentially expressed lncRNA in patient samples when compared to normal samples.
| Gene Symbol | Gene ID   | Accession  | Description                                                                                                                                   | Length | Regulation ([A] Vs [B]) | FC (abs) ([A] Vs [B]) | p ([A] Vs [B]) | Type            |
|-------------|-----------|------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|-----------------------|----------------|-----------------|
| LOC105371291 | 105371291 | XR_933627.3 | uncharacterized LOC105371291, transcript variant X3                                                                                         | 1138   | down                    | 12.056273             | 0.01451713    | ncRNA           |
| LOC105374803 | 105374803 | XR_940242.2 | uncharacterized LOC105374803                                                                                                                  | 1305   | down                    | 9.0651                | 0.00494713    | ncRNA           |
| LINC00261    | 140828    | NR_001558.3 | long intergenic non-protein coding RNA 261                                                                                                   | 4912   | down                    | 7.9187694            | 0.01998967    | ncRNA           |
| PSORS1C3     | 100130889 | NR_152831.1 | psoriasis susceptibility 1 candidate 3 (non-protein coding), transcript variant 5                                                            | 624    | down                    | 6.993259             | 0.01583394    | ncRNA           |
| LOC112267956 | 112267956 | XR_002956345.1 | uncharacterized LOC112267956                                                                                                             | 2005   | down                    | 6.9718432            | 0.01816426    | ncRNA           |
| LOC158434    | 158434    | NR_132344.1 | uncharacterized LOC158434                                                                                                                    | 2662   | down                    | 6.0362997            | 0.00271874    | ncRNA           |
| LOC105372653 | 105372653 | NR_134564.1 | uncharacterized LOC105372653                                                                                                                  | 573    | down                    | 5.8000107            | 2.83E-04      | ncRNA           |
| LINC01320    | 104355288 | NR_126404.1 | long intergenic non-protein coding RNA 1320                                                                                                  | 1131   | down                    | 5.6668267            | 0.01277497    | ncRNA           |
| LOC105371825 | 105371825 | XR_001752940.1 | uncharacterized LOC105371825                                                                                                            | 3133   | down                    | 5.4514194            | 0.02630284    | ncRNA           |
| PP7080       | 25845     | NR_024158.1 | uncharacterized LOC25845                                                                                                                     | 1743   | down                    | 5.4081116            | 0.01141873    | ncRNA           |
| LOC105369381 | 105369381 | XR_001748496.1 | uncharacterized LOC105369381, transcript variant X2                                                                                     | 5254   | down                    | 5.392252            | 0.00472638    | ncRNA           |
| EMX2OS       | 196047    | NR_144378.1 | EMX2 opposite strand/antisense RNA, transcript variant 2                                                                                   | 7201   | down                    | 5.325151            | 0.00589902    | ncRNA           |
| SNORA25B     | 109623459 | NR_145801.1 | small nucleolar RNA, H/ACA box 25B                                                                                                          | 127    | down                    | 5.319602            | 0.00461494    | ncRNA           |
| LOC101928875 | 101928875 | XR_001748392.2 | uncharacterized LOC101928875                                                                                                          | 728    | down                    | 5.1403937            | 0.006804      | ncRNA           |
| GBA3         | 57733     | NR_102356.1 | glucosylceramidase beta 3 (gene/pseudogene), transcript variant 2, non-coding                                                              | 1243   | down                    | 5.103703            | 0.00271457    | ncRNA           |
| LOC101927269 | 101927269 | NR_110075.1 | uncharacterized LOC101927269                                                                                                                 | 507    | down                    | 4.978601             | 0.03097457    | ncRNA           |
| LOC105377924 | 105377924 | NR_134603.1 | uncharacterized LOC105377924                                                                                                                | 415    | down                    | 4.938898             | 0.0150742     | ncRNA           |
| LOC105374510 | 105374510 | XR_001741602.1 | uncharacterized LOC105374510, transcript variant X3                                                                                        | 4802   | down                    | 4.9087567            | 0.03875371    | ncRNA           |
| LOC102724834 | 102724834 | XR_429171.4 | uncharacterized LOC102724834                                                                                                                 | 3131   | down                    | 4.588613            | 0.0016174     | ncRNA           |
| LOC107985242 | 107985242 | XR_001738352.1 | uncharacterized LOC107985242,                                                                                                              | 1899   | down                    | 4.5234885             | 0.00128315   | ncRNA           |
| Transcript | Entrez Gene | NCBI Reference | Description | Log2 Fold Change | p-Value | Differential Expression Status | Enrichment | Evidence |
|------------|-------------|----------------|-------------|-----------------|---------|-----------------------------|------------|---------|
| LOC105378608 | 105378608 | XR_946886.2 | uncharacterized LOC105378608 | 3022 | up | 14.387957 | 0.0011432 | ncRNA |
| LOC105376384 | 105376384 | XR_930616.3 | uncharacterized LOC105376384, transcript variant X3 | 1188 | up | 6.8661094 | 9.25E-04 | ncRNA |
| HECW1-IT1 | 100127950 | NR_135295.1 | HECW1 intronic transcript 1 | 1839 | up | 6.84244 | 0.0338196 | ncRNA |
| LOC105371401 | 105371401 | XR_002957935.1 | uncharacterized LOC105371401 | 3094 | up | 6.693866 | 0.0253292 | ncRNA |
| CASC23 | 103581031 | NR_125366.1 | cancer susceptibility 23 (non-protein coding) | 1583 | up | 6.3594065 | 0.0033188 | ncRNA |
| LOC105374641 | 105374641 | XR_925740.2 | uncharacterized LOC105374641 | 294 | up | 5.8032284 | 0.0058914 | ncRNA |
| LOC105379057 | 105379057 | XR_001743976.1 | uncharacterized LOC105379057, transcript variant X2 | 770 | up | 5.3314576 | 0.0160089 | ncRNA |
| LINC00578 | 100505566 | NR_047568.1 | long intergenic non-protein coding RNA 578 | 1222 | up | 5.320564 | 0.0322535 | ncRNA |
| MIR4435-2HG | 541471 | NR_136164.1 | MIR4435-2 host gene, transcript variant 6 | 2046 | up | 5.3023853 | 0.0074196 | ncRNA |
| LOC107984270 | 107984270 | XR_001743976.1 | uncharacterized LOC105374641, transcript variant X2 | 770 | up | 5.3314576 | 0.0160089 | ncRNA |
| MIR503HG | 84848 | NR_024607.1 | MIR503 host gene | 786 | up | 5.049058 | 0.0020093 | ncRNA |
| ADAM5 | 255926 | NR_001448.1 | ADAM metallopeptidase domain 5 (pseudogene) | 1718 | up | 5.048116 | 9.81E-04 | ncRNA |
| MIR8061 | 102466251 | NR_107028.1 | microRNA 8061 | 75 | up | 4.843885 | 5.84E-04 | ncRNA |
| LOC105375855 | 105375855 | XR_928920.2 | uncharacterized LOC105375855 | 7758 | up | 4.6685147 | 0.0167273 | ncRNA |
| SH3RF3-AS1 | 100287216 | NR_029193.1 | SH3RF3 antisense RNA 1 | 2793 | up | 4.144925 | 0.0178191 | ncRNA |
| LOC100506688 | 100506688 | NR_104615.1 | uncharacterized LOC100506688, transcript variant 2 | 3451 | up | 4.080634 | 0.0015401 | ncRNA |
| LOC107986185 | 107986185 | XR_001743976.1 | uncharacterized LOC107986185 | 513 | up | 3.9532552 | 4.36E-05 | ncRNA |
| LOC107986821 | 107986821 | XR_001743976.1 | uncharacterized LOC107986821, transcript variant X1 | 3257 | up | 3.8777435 | 0.0174942 | ncRNA |
| LOC105373592 | 105373592 | XR_001739685.2 | uncharacterized LOC105373592, transcript variant X2 | 877 | up | 3.8124175 | 0.0061617 | ncRNA |
Figures

Figure 1  
Principal component analysis (PCA,1A) results of differentiated lncRNA and heatmap(1B).

**Figure 2**  
Functional analysis of differentially expressed genes with GO enrichment analysis.
Figure 3

Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis with the differentially expressed lncRNAs.
Figure 4

5 IncRNAs were related with cis target genes in PBM.
Figure 5

The trans-target prediction analysis of differentially expressed IncRNAs in PBM.
Figure 6

The functional distribution of differentially expressed lncRNAs with TF analysis.

Figure 7

Validation of the microarray test by qPCR.
ROC analysis of genes NR_110876, NR_132344, XR_946886, XR_002956345 with AUC.